Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01481-6
Abstract: Ravulizumab (Ultomiris®), a humanized monoclonal antibody that inhibits complement protein C5, is indicated for the treatment of atypical haemolytic uraemic syndrome (aHUS) in several countries, including the USA and those of the EU. Ravulizumab has… read more here.
Keywords: treatment; uraemic syndrome; ravulizumab; atypical haemolytic ... See more keywords
Various phenotypes of disease associated with mutated DGKE gene.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of medical genetics"
DOI: 10.1016/j.ejmg.2020.103953
Abstract: Atypical haemolytic uraemic syndrome and steroid-resistant nephrotic syndrome are highlyrare kidney diseases that can occur in childhood. In some cases, genetic variants may trigger these conditions, although in atypical haemolytic uraemic syndrome they mostly confer… read more here.
Keywords: resistant nephrotic; uraemic syndrome; atypical haemolytic; steroid resistant ... See more keywords
MO020EFFICACY AND SAFETY OF THE LONG-ACTING C5 INHIBITOR RAVULIZUMAB IN PATIENTS WITH POSTPARTUM ATYPICAL HAEMOLYTIC URAEMIC SYNDROME
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa140.mo020
Abstract: Atypical haemolytic uraemic syndrome (aHUS) triggered by pregnancy is a rare and under-recognised disease caused by dysregulation of the alternative complement pathway that occurs in approximately 1 in 25,000 pregnancies. The 311 phase 3 trial… read more here.
Keywords: patients postpartum; inhibitor; ravulizumab; atypical haemolytic ... See more keywords
Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan
Sign Up to like & getrecommendations! Published in 2022 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfac150
Abstract: ABSTRACT Background Eculizumab was approved for atypical haemolytic uraemic syndrome (aHUS) in Japan in 2013. Post-marketing surveillance (PMS) was mandated by regulatory authorities to assess the safety and effectiveness of eculizumab in patients with aHUS… read more here.
Keywords: haemolytic uraemic; paediatric patients; atypical haemolytic; uraemic syndrome ... See more keywords
Eculizumab in secondary atypical haemolytic uraemic syndrome
Sign Up to like & getrecommendations! Published in 2017 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfw453
Abstract: Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab. Methods. We identified 29… read more here.
Keywords: nephrology; treatment; uraemic syndrome; atypical haemolytic ... See more keywords
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.15790
Abstract: Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long‐term pharmacovigilance is unknown. This analysis summarises safety data collected… read more here.
Keywords: nocturnal haemoglobinuria; uraemic syndrome; infection; atypical haemolytic ... See more keywords
The role of anti‐complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16297
Abstract: Atypical haemolytic uremic syndrome (aHUS) is associated with complement system abnormality, such as production of complement factor H (CFH) autoantibodies. The growing evidence indicates complement overactivation on platelets is intimately involved in aHUS pathogenesis, besides… read more here.
Keywords: haemolytic uremic; uremic syndrome; complement factor; anti cfh ... See more keywords
Eculizumab in paediatric atypical haemolytic uraemic syndrome: Lessons learned from a single‐centre experience in the United Arab Emirates
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Paediatrics and Child Health"
DOI: 10.1111/jpc.14390
Abstract: Atypical haemolytic uraemic syndrome (aHUS) is a debilitating condition that can cause significant morbidity and mortality in children if not adequately and promptly treated. This report shares real‐world data on the use of eculizumab in… read more here.
Keywords: uraemic syndrome; atypical haemolytic; paediatric atypical; eculizumab paediatric ... See more keywords
Life‐threatening pregnancy‐associated atypical haemolytic uraemic syndrome and its response to eculizumab
Sign Up to like & getrecommendations! Published in 2017 at "Nephrology"
DOI: 10.1111/nep.12938
Abstract: Pregnancy‐associated atypical haemolytic uraemic syndrome (P‐aHUS) is a rare, potentially lethal condition that can complicate pregnancy in up to 1 in 25 000 cases. Without prompt diagnosis and initiation of appropriate treatment, this condition can… read more here.
Keywords: pregnancy; uraemic syndrome; atypical haemolytic; haemolytic uraemic ... See more keywords
Recurrent case of pregnancy-induced atypical haemolytic uremic syndrome (P-aHUS)
Sign Up to like & getrecommendations! Published in 2019 at "BMJ Case Reports"
DOI: 10.1136/bcr-2018-226571
Abstract: Pregnancy-induced atypical haemolytic uremic syndrome (P-aHUS) is a rare condition characterised by microangiopathic haemolytic anaemia, thrombocytopenia and renal failure. It accounts for approximately 7% of total HUS cases. Here, we present a case of recurrent… read more here.
Keywords: haemolytic uremic; pregnancy; pregnancy induced; atypical haemolytic ... See more keywords
Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2021-054536
Abstract: Introduction Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disease caused by excessive activation of part of the immune system called complement. Eculizumab is an effective treatment, controlling aHUS in 90% of patients. Due… read more here.
Keywords: haemolytic uraemic; atypical haemolytic; uraemic syndrome; treatment ... See more keywords